Abstract
sRAGE acts as a decoy for RAGE ligands to inhibit inflammation and cell injury and have been suggested as a new biomarker for asthma. Reduced levels of sRAGE are found in COPD and neutrophilic asthma. Moreover, FeNO and sRAGE serum levels are negatively correlated in children with recurrent wheezing. We aimed to evaluate the sRAGE serum level according to asthma control and exacerbation status in children. <b>Methods:</b> In total, 101 children aged 7-18 referred to a pediatric allergy centre (Krasnoyarsk, Russia) were divided into three groups: controlled (n=45), partially controlled (n=19), and uncontrolled asthma (n=37) according to GINA-2020. Control group was represented by 92 age- and sex-matched none-asthmatics. Serum sRAGE levels were measured using a magnetic immunoassay (MAGPIX). Kruskal-Wallis test was used. <b>Results:</b> Serum sRAGE level was reduced only in uncontrolled asthmatics (Fig. 1, p (Kruskal-Wallis test) = 0.001). Additionally, serum sRAGE levels were decreased in asthma exacerbation groups, regardless of virus-induced/allergen-induced exacerbation status. <b>Conclusion:</b> Serum sRAGE level is closely related to asthma control and exacerbation status in asthmatic children and may be used as a new marker of control losing and, possible, as a target for intervention.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call